Singapore, Dec 31, 2009: Affomix, a US-based developer of automated, high-throughput monoclonal antibody selection technology has said that Kalgene Pharmaceuticals has signed a commercial agreement to have Affomix utilize its Y2HExpress technology to select antibodies with potential diagnostic and therapeutic utility in breast cancer.
Kalgene Pharmaceuticals is a private company focused on the development of oncology therapeutics and companion diagnostics. The company's portfolio of oncology products is at various stages in development, from assay development to advanced clinical trials.
"After much diligence, Kalgene chose Affomix as the company to rapidly procure antibodies against our proprietary targets", said Dr. T. Nathan Yoganathan, President and CEO of Kalgene Pharmaceuticals. "Y2HExpress has the ability to select antibodies at an unprecedented level of specificity, combined with very favorable financial advantages," Yoganathan continued.
"The application of Affomix technology will accelerate our product development schedule", said Robert Davidson, Director of Science and Technology for Kalgene.
"Our automated high-throughput procedures allow us to quickly identify highly specific antibodies against predetermined regions of target proteins. These antibodies are well suited for experimental use while serving as ideal starting points for development of diagnostic and therapeutic agents", said Michael Sherman, President of Affomix.
| 
Comment on this article
